Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients undergoing surgery for metastatic spinal disease. Published series report 90-day symptomatic VTE rates of 11-15% in this population, with a substantial proportion of events occurring after hospital discharge when standard inpatient prophylaxis has ceased. Current guidelines from ASCO and ACCP recommend extended pharmacologic VTE prophylaxis (4 weeks postoperatively) following major abdominal and pelvic cancer surgery, supported by evidence from the ENOXACAN II trial and others. However, no guidelines or prospective data exist regarding extended VTE prophylaxis after spinal surgery for metastatic disease, despite comparable or greater VTE risk.

A retrospective analysis of 68 consecutive patients who underwent surgery for spinal metastatic disease at UPMC between January 2022 and December 2024 identified a 90-day symptomatic VTE rate of 14.7% (10/68) and a 90-day all-cause mortality rate of 16% (11/68), confirming the high burden of this complication in the local population.

This is a single-arm, prospective, open-label interventional pilot study evaluating extended prophylactic anticoagulation with apixaban 2.5 mg orally twice daily for 30 days following hospital discharge. The study population consists of adults (≥18 years) who have undergone spinal surgery for vertebral metastatic disease at UPMC Presbyterian, Shadyside, or Mercy hospitals. Key exclusion criteria include active therapeutic anticoagulation, active bleeding, severe hepatic or renal impairment, concurrent use of strong CYP3A4/P-gp inhibitors or inducers, and inability to discontinue antiplatelet agents or chronic NSAIDs.

Apixaban 2.5 mg BID is FDA-approved for VTE prophylaxis following hip replacement (35 days) and knee replacement (12 days). The proposed dose and route are identical to the approved prophylactic regimen. In the ADVANCE-3 trial, apixaban 2.5 mg BID demonstrated superior efficacy to enoxaparin with major bleeding rates of 0.8% vs 0.7%. The AVERT trial demonstrated a 59% reduction in VTE with apixaban 2.5 mg BID in ambulatory cancer patients at intermediate-to-high VTE risk.

The primary endpoint is the incidence of symptomatic VTE (DVT and/or PE) within 90 days of hospital discharge. Key secondary endpoints include major bleeding events (ISTH criteria), clinically relevant non-major bleeding events (ISTH criteria), and all-cause mortality at 90 days. Additional secondary endpoints include medication adherence (pill count at Day 31), spinal epidural hematoma requiring intervention, hospital readmission rates, and emergency department visits within 90 days.

Follow-up consists of telephone calls at approximately Day 2, Day 31, and Day 91 post-discharge, supplemented by periodic medical record review. No additional clinic visits are required.

Outcomes in the prospective cohort (target N=50) will be compared to the historical control cohort (N=68). The primary statistical analysis uses a Bayesian comparison of binomial proportions with a uniform (non-informative) prior distribution. Based on Bayesian power calculations, with 50 enrolled subjects and accounting for an expected 16% attrition from mortality and loss to follow-up (yielding approximately 40-42 evaluable subjects), a 46% reduction in VTE incidence would provide an 85.2% posterior probability of benefit, and a 59% reduction would provide a 92.3% posterior probability of benefit.

Stopping rules are pre-specified: enrollment will be paused if ≥2 major bleeding events or ≥4 clinically relevant non-major bleeding events occur. Any single fatal bleeding event or spinal epidural hematoma will trigger immediate safety review. An independent safety monitor provides oversight.

This study is conducted under an IND exemption per 21 CFR 312.2(b)(1). Results will inform the design and sample size of a future multicenter randomized controlled trial.